SRDX
Surmodics, Inc.

208
Mkt Cap
$614.51M
Volume
5.34M
52W High
$43.00
52W Low
$25.87
PE Ratio
-34.75
SRDX Fundamentals
Price
$42.98
Prev Close
$42.83
Open
$42.87
50D MA
$30.90
Beta
0.63
Avg. Volume
92,646.43
EPS (Annual)
-$0.8155
P/B
5.52
Rev/Employee
$324,107.97
Loading...
Loading...
News
all
press releases
Surmodics (NASDAQ:SRDX) Sees Unusually-High Trading Volume - Here's What Happened
Surmodics (NASDAQ:SRDX) Sees Strong Trading Volume - Still a Buy...
MarketBeat·1d ago
News Placeholder
More News
News Placeholder
Best Small Cap Stocks Worth Watching - November 17th
Leap Therapeutics, Spring Valley Acquisition, and Surmodics are the three Small Cap stocks to watch today, according to MarketBeat's stock screener tool. Small-cap stocks are shares of publicly...
MarketBeat·2d ago
News Placeholder
Surmodics Target of Unusually High Options Trading (NASDAQ:SRDX)
Surmodics, Inc. (NASDAQ:SRDX - Get Free Report) was the target of some unusual options trading on Monday. Stock investors bought 13,635 call options on the stock. This represents an increase of...
MarketBeat·2d ago
News Placeholder
Surmodics (NASDAQ:SRDX) Sets New 52-Week High - Still a Buy?
Surmodics (NASDAQ:SRDX) Sets New 1-Year High - Here's What Happened...
MarketBeat·2d ago
News Placeholder
Surmodics Announces FTC Does Not Intend to Appeal Denial of Injunction, Order Preventing Closing Set to Expire Today
Surmodics, Inc. (Nasdaq: SRDX) (Surmodics or the Company), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that it expects to...
Business Wire·3d ago
News Placeholder
Surmodics (NASDAQ:SRDX) Earns Underperform Rating from Barrington Research
Barrington Research downgraded Surmodics from a "market perform" rating to an "underperform" rating in a research report on Friday...
MarketBeat·5d ago
News Placeholder
Fortress Biotech (FBIO) Surpasses Q3 Earnings Estimates
Fortress Biotech (FBIO) delivered earnings and revenue surprises of +125.58% and -25.55%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·6d ago
News Placeholder
63,050 Shares in Surmodics, Inc. $SRDX Acquired by Thompson Davis & CO. Inc.
Thompson Davis & CO. Inc. acquired a new stake in Surmodics, Inc. (NASDAQ:SRDX - Free Report) in the second quarter, according to the company in its most recent filing with the Securities and...
MarketBeat·6d ago
News Placeholder
TriSalus Life Sciences, Inc. (TLSI) Reports Q3 Loss, Tops Revenue Estimates
TriSalus Life Sciences, Inc. (TLSI) delivered earnings and revenue surprises of -464.71% and +0.79%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·7d ago
News Placeholder
Surmodics (NASDAQ:SRDX) Sees Unusually-High Trading Volume - Still a Buy?
Surmodics (NASDAQ:SRDX) Sees Unusually-High Trading Volume - Here's What Happened...
MarketBeat·7d ago

Latest SRDX News

View

Advertisement|Remove ads.

Advertisement|Remove ads.